Peder L Myhre

Peder L Myhre is an expert in Cardiology at Oslo University Hospital (Norway). As of October 2026, ScienceLeadR ranks Peder L Myhre in the top 1% of experts worldwide for Heart Failure. Peder L Myhre has authored 188 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 3 of them ongoing. SLR score: 1,101 (community average: 125). How the SLR is computed.

Cardiology

Subspecialties: Public Health - Biochemistry - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 30, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2012 - 2026

Source: PubMed

Akershus University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 188

Citations

Citations: 2 456 1st author: 69 Last author: 23 Unique author: 3

Main journals

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
Enhancing heart failure care through registries: lessons learned from Nordic Countries' implementation of guidelines. PMID 41789668 — registries, heart failure, heart, heart failure, systolic, therapeutics	Eur J Heart Fail	2026
Redefining Cardiometabolic Disease: Expert Consensus on the CardioVascular-Kidney-Liver-Metabolic (CVKLM) Multiorgan Staging. PMID 42945405 — liver diseases, diabetes mellitus, heart, cardiovascular diseases, kidney, liver, obesity, therapeutics	Eur J Prev Cardiol	2026
The complexity of congestion in heart failure: a critical review of the evidence and a proposal for a multimodality approach. PMID 42895733 — hospitalization, heart failure, heart, cardiovascular diseases, tissues	Eur Heart J Qual Care Clin Outcomes	2026
Implications of Serum Transthyretin to NT-proBNP Ratio in Transthyretin Amyloid Cardiomyopathy: Insights From ATTRibute-CM. PMID 42862130 — serum, heart failure, prealbumin, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy	JACC Heart Fail	2026
Device therapies in cardiorenal syndrome: an expert review. PMID 42611536 — heart failure, diuretics, therapeutics, cardio-renal syndrome	ESC Heart Fail	2026

Clinical Studies 16

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 7

Phase 3 6

Phase 4 3

By status:

Completed 8

Unknown 3

Recruiting 2

Active not recruiting 1

Not yet recruiting 1

Terminated 1

By type:

Interventional 13

Observational 3

By Monocentric/Multicentric:

monocentric 2

multicentric2to4 3

multicentric5to9 1

multicentricup10 10

Main Topics

Cardiovascular Diseases 12

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
EASi PROTKT A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes high blood pressure and cardiovascular disease 2025-521188-11-00 — diabetes mellitus, hypertension, safety, blood, cardiovascular diseases, blood pressure, diabetes mellitus, type 2	Phase 3	Recruiting	2025
Vexus Assessment and Natriuresis guided Diuretic Therapy in Acute Heart Failure NCT07558798 — hyperemia, mortality, heart failure, heart, natriuresis, diuretics, therapeutics	N/A	Not yet recruiting	2026
Management of Patients With Heart Failure at Home After Hospital Discharge NCT06576752 — monitoring, ambulatory, safety, heart failure, heart, ambulatory care facilities, outpatient clinics, hospital, maximum tolerated dose, outpatients, digital health	N/A	Recruiting	2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice